You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 21, 2025

Claims for Patent: 6,524,570

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,524,570

Title:	Polyethylene glycol modified interferon therapy
Abstract:	A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.
Inventor(s):	Glue; Paul (Flemington, NJ), Cutler; David L. (Morristown, NJ), Affrime; Melton B. (Flemington, NJ)
Assignee:	Schering Corporation (Kanilworth, NJ)
Application Number:	09/699,663
Patent Claims:	1. A method of treating a patient suspected of having hepatitis C infection, comprising administering to the patient a conjugate comprising polyethylene glycol (PEG) and an alpha interferon once per week in an amount effective to treat the infection. 2. The method of claim 1 wherein said interferon is interferon alpha-2a. 3. The method of claim 1 wherein said interferon is interferon alpha-2b. 4. The method of claim 1 wherein said interferon comprises consensus alpha interferon. 5. The method of claim 1 wherein said interferon comprises naturally occurring alpha interferon. 6. The method of claim 1 wherein said interferon comprises recombinant alpha interferon. 7. The method of claim 1 wherein the amount of the conjugate administered is 0.5 .mu.g/kg. 8. The method of claim 1 wherein the amount of the conjugate administered is 2.0 .mu.g/kg. 9. The method of claim 1 wherein the amount of the conjugate administered is 0.5, 1.0, or 1.5 .mu.g/kg. 10. The method of claim 1 wherein said PEG is conjugated to said alpha interferon via an epsilon amino group of a lysine residue in said alpha interferon. 11. The method of claim 1 wherein said PEG is conjugated to free amino groups of said alpha interferon via a urethane linkage. 12. A method of treating a patient suspected of having hepatitis C infection, comprising administering to the patient a conjugate comprising polyethylene glycol (PEG) and an alpha interferon once or twice per week in an amount effective to treat the infection. 13. The method of claim 12 wherein said interferon is interferon alpha-2a. 14. The method of claim 12 wherein said interferon is interferon alpha-2b. 15. The method of claim 12 wherein said interferon comprises consensus alpha interferon. 16. The method of claim 12 wherein said interferon comprises naturally occurring alpha interferon. 17. The method of claim 12 wherein said interferon comprises recombinant alpha interferon. 18. The method of claim 12 wherein the amount of the conjugate administered is 0.5 .mu.g/kg. 19. The method of claim 12 wherein the amount of the conjugate administered is 2.0 .mu.g/kg. 20. The method of claim 12 wherein the amount of the conjugate administered is 0.5, 1.0, or 1.5 .mu.g/kg. 21. The method of claim 12 wherein said PEG is conjugated via an epsilon amino group of a lysine residue in said interferon alpha. 22. The method of claim 12 wherein said PEG is conjugated to free amino groups of said interferon alpha via a urethane linkage. 23. The method of claim 12 wherein said conjugate is administered to said patient twice per week. 24. A method of treating a patient suspected of having hepatitis C infection, comprising administering to the patient in combination, ribavirin and a conjugate comprising polyethylene glycol (PEG) and an alpha-interferon, each in amounts effective to treat the infection, wherein the conjugate is administered once or twice per week. 25. The method of claim 24 wherein said interferon is interferon alpha-2a. 26. The method of claim 24 wherein said interferon is interferon alpha-2b. 27. The method of claim 24 wherein said interferon comprises consensus alpha interferon. 28. The method of claim 24 wherein said interferon comprises naturally occurring alpha interferon. 29. The method of claim 24 wherein said interferon comprises recombinant alpha interferon. 30. The method of claim 25 wherein the amount of the conjugate administered is 0.5 .mu.g/kg. 31. The method of claim 25 wherein the amount of the conjugate administered is 2.0 .mu.g/kg. 32. The method of claim 25 wherein the amount of the conjugate administered is 0.5, 1.0, or 1.5 .mu.g/kg. 33. The method of claim 25 wherein said PEG is conjugated to said alpha interferon via an epsilon amino group of a lysine residue in said alpha interferon. 34. The method of claim 25 wherein said PEG is conjugated to free amino groups of said alpha interferon via a urethane linkage. 35. The method of claim 24 wherein the conjugate is administered once per week. 36. The method of claim 24 wherein the conjugate is administered twice per week.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.